Ryan K. Shields, PharmD, MS

Ryan Shields, PharmD, MS, discusses the challenges of incorporating newer antibiotics for Gram-negative infections, how he is using broad-spectrum antimicrobial agents for these infections, and the factors he looks for in considering new agents.

Panelists discuss the pivotal role of microbiology laboratories and rapid diagnostic technologies in managing multidrug-resistant infections, highlighting their impact on timely treatment, antibiotic stewardship, and the need for interdisciplinary collaboration to effectively interpret and act on resistance data.

Panelists discuss emerging therapies for multidrug-resistant Gram-negative pathogens, focusing on the rising threat of antimicrobial resistance, evolving resistance mechanisms like extended-spectrum β-lactamases (ESBLs) and New Delhi metallo-β-lactamases (NDMs), regional variability in pathogen prevalence, and the clinical implications for treatment in inpatient and outpatient settings.

Resistance against this pathogen with β-lactamase medications can vary according to geographic region.

Rates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.

Carbapenem-resistant Enterobacterales present considerable treatment challenges. Recent cumulative evidence supports preference for therapies.

Recent study results show promising new modalities.

This approach can help with clinical outcomes and mortality, but resistance is not as well defined.

Ceftazidime-avibactam is a novel treatment for CRE infections, but reports of resistance are increasing.